Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Key role of the cyclin-dependent kinase inhibitor p27kip1 for embryonal carcinoma cell survival and differentiation

Abstract

Hexamethylen-bisacetamide (HMBA) represents the prototype of a group of hybrid polar compounds, which induce differentiation in a variety of transformed cells including human embryonal carcinoma cells. Therefore, HMBA has been used in the differentiation therapy of cancer for patients with both hematological and solid malignancies. Upon HMBA treatment, the embryonal carcinoma cell line NTERA-2 clone D1 (NT2/D1) accumulates in G1 and undergoes terminal differentiation. Here we demonstrate that growth arrest and differentiation of NT2/D1 cells induced by HMBA involve increased expression of the cyclin-dependent kinase inhibitor p27, enhanced association of p27 with cyclin E/CDK2 complexes and suppression of kinase activity associated to cyclin E/CDK2 (but not to cyclin D3/CDK4). When HMBA differentiation was induced in the presence of p27 antisense oligonucleotides, NT2/D1 cells failed to arrest growth properly and, in parallel with the reduction of the anti-apoptotic Bcl-2 gene expression, cells underwent massive programmed cell death. Conversely, constitutive expression of p27 into NT2/D1 cells induced a marked reduction in the growth potential of these cells and partially reproduced HMBA-induced modification of surface antigen expression (down-regulation of SSEA-3 expression and up-regulation of VINIS-53 expression). Expression of p21 induced growth arrest but not differentiation. Likewise, inhibition of CDK2 by transfection of a dominant negative CDK2 in NT2/D1 cells or treatment with the kinase inhibitor olomucine induced growth arrest but not differentiation. Therefore, we propose that p27 represents a crucial molecule in HMBA signaling that cannot be replaced by p21. Furthermore, the results obtained with CDK2 inhibitors demonstrate that the block of CDK2 activity is sufficient for growth arrest but not for cell differentiation and suggest that, at least in these cells, growth arrest and differentiation are regulated by two overlapping but different pathways.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  • Alessi F, Quarta S, Savio M, Riva F, Rossi L, Stivala LA, Scovassi AI, Meijer L and Prosperi E. . 1998 Exp. Cell Res. 245: 8–18.

  • Andreeff M, Stone R, Michaeli J, Young CW, Tong WP, Ervin T, Kufe D, Rifkind RA and Marks PA. . 1992 Blood 80: 2604–2609.

  • Andrews PW. . 1984 Develop. Biol. 103: 285–293.

  • Andrews PW, Nudelman E, Hakomori S and Fenderson BA. . 1990 Differentiation 43: 131–138.

  • Baldassarre G, Romano A, Armenante F, Rambaldi M, Paoletti I, Sandomenico C, Pepe S, Staibano S, Salvatore G, De Rosa G, Persico MG and Viglietto G. . 1997 Oncogene 15: 927–936.

  • Casaccia-Bonnefil P, Tikoo R, Kiyokawa H, Friederich V, Chao MV and Koff A. . 1997 Genes Dev. 11: 2335–2346.

  • Chalfie M, Tu Y, Euskirchen G, Ward WW and Prasher DC. . 1994 Science 263: 802–805.

  • Coats S, Flanagan WM, Nourse J and Roberts JM. . 1996 Science 272: 877–880.

  • Conley BA, Egorin MJ, Sinibaldi V, Sewack G, Kloc C, Roberts L, Zuhowski EG, Forrest A and Van Echo DA. . 1992 Cancer Chemot. Pharm. 31: 37–45.

  • Craig C, Wersto R, Kim M, Ohri E, Li Z, Katayose D, Lee SJ, Trepel J, Cowan K and Seth P. . 1997 Oncogene 14: 2283–2289.

  • Di Cunto F, Topley G, Calautti E, Hsiao J, Ong L, Seth PK and Dotto GP. . 1998 Science 280: 1069–1072.

  • Dobashi Y, Kudoh T, Matsumine A, Toyoshima K and Akiyama T. . 1995 J. Biol. Chem. 270: 23031–23037.

  • El-Deiry WS, Tokino T, Velculesco VE, Levy DB, Parson R, Trent JM, Lin D, Mercer EW, Kinzler KW and Vogelstein B. . 1993 Cell 75: 817–825.

  • Firpo EJ, Koff A, Solomon MJ and Roberts JM. . 1994 Mol. Cell. Biol. 14: 4889–4901.

  • Gil-Gomez G, Berns A and Brady HJM. . 1998 EMBO J. 17: 7209–7218.

  • Guo K, Wang JY, Andres V, Smith RC and Walsh K. . 1995 Mol. Cell. Biol. 15: 3823–3829.

  • Hunter T and Pines J. . 1994 Cell 79: 573–582.

  • Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hofmann ES, Ono M, Khanam D, Hayday AC, Frohman LA and Koff A. . 1996 Cell 85: 721–732.

  • Kiyokawa H, Richon VM, Rifkind RA and Marks PA. . 1994 Mol. Cell. Biol. 14: 7195–7203.

  • Kranenburg O and Zantema A. . 1995 FEBS Lett. 367: 103–106.

  • Levkau B, Koyoama H, Raines EW, Clurman BE, Herren B, Orth K, Roberts JM and Ross R. . 1998 Mol. Cell 1: 553–563.

  • Liu M, Lee MH, Cohen M, Bommakanti M and Freedman L. . 1996 Genes Dev. 10: 142–153.

  • Liu J, Flanagan WM, Drazba JA, Estes ML, Barnett GH, Haqqi T, Kondo S and Barna BP. . 1997 J. Immunol. 159: 812–819.

  • Marks PA, Sheffrey M and Rifkind RA. . 1987 Cancer Res. 47: 659–666.

  • Miekrantz W and Schlegel R. . 1995 J. Cell Biochem. 58: 160–174.

  • Missero C, Di Cunto F, Kiyokawa H, Koff A and Dotti GP. . 1996 Genes Dev. 10: 3065–3075.

  • O'Reilly LA, Huang DCS and Strasser A. . 1996 EMBO J. 15: 6979–6990.

  • Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF and Rolfe M. . 1995 Science 269: 682–685.

  • Poluha W, Poluha DK, Chang B, Crosbie NE, Schonhoff CM, Kilpatrick DL and Ross AH. . 1996 Mol. Cell. Biol. 16: 1335–1341.

  • Polyak K, Lee M, Koff A, Roberts JM and Massaguè J. . 1994 Cell 78: 59–66.

  • Richon VM, Webb Y, Merger R, Sheppard T, Jursic B, Ngo L, Civoli F, Breslow R, Rifkind RA and Marks PA. . 1996 Proc. Natl. Acad. Sci. USA 93: 5705–5708.

  • Sambrook J, Fritsch EF and Maniatis T. . 1992 Molecular Cloning: A laboratory manual. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, New York.

    Google Scholar 

  • Schutte B, Nieland L, van Engeland M, Henfling ME, Meijer L and Ramaekers FC. . 1997 Exp. Cell Res. 236: 4–15.

  • Sentman CL, Shutter JR, Hocknbery D, Kanagawa O and Korsmayer SJ. . 1991 Cell 67: 879–888.

  • Sherr CJ and Roberts JM. . 1995 Genes Dev. 9: 1149–1163.

  • Sherr CJ. . 1994 Cell 79: 551–555.

  • Shevinsky LH, Knowles BB, Damjanov I and Solter D. . 1982 Cell 30: 697–705.

  • van den Heuvel S and Harlow E. . 1993 Science 262: 2050–2054.

  • Wang J and Walsh K. . 1996 Science 273: 359–361.

  • Wang X, Gorospe M, Huang Y and Holbrook NJ. . 1997 Oncogene 15: 2991–2997.

  • Weinberg RA. . 1995 Cell 81: 323–330.

  • White E. . 1996 Genes Dev. 10: 1–15.

  • Young CW, Fanucchi MP, Walsh TD, Baltzer L, Yaldaei S, Stevens YW, Gordon C, Tong W, Rifkind MA and Marks PA. . 1988 Cancer Res. 48: 7304–7309.

Download references

Acknowledgements

This work was supported by Associazione Italiana Ricerca sul Cancro (AIRC) and Progetto Finalizzato Biotecnologie of the CNR. We are indebted to Dr PW Andrew for kindly providing the differentiation-specific antibodies and to Dr G Draetta for providing the dominant negative CDK2 plasmid. G Baldassarre, B Belletti, A Boccia and P Bruni are supported by fellowships from the Federazione Italiana Ricerca sul Cancro (FIRC).

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Baldassarre, G., Barone, M., Belletti, B. et al. Key role of the cyclin-dependent kinase inhibitor p27kip1 for embryonal carcinoma cell survival and differentiation. Oncogene 18, 6241–6251 (1999). https://doi.org/10.1038/sj.onc.1203031

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1203031

Keywords

This article is cited by

Search

Quick links